Related Experiment Video
Updated: Aug 22, 2026
Mimicking and Manipulating Pancreatic Acinar-to-Ductal Metaplasia in 3-dimensional Cell Culture
Published on: February 11, 2019
Elucidating the mechanism of ADAM10/PD-L1 interaction in pancreatic adenocarcinoma cell lines using cellular and
Ahmed M E Abdalla1,2, Yu Miao3,4, Yasir A Taha5
1School of Biological Sciences and Technology, University of Jinan, Jinan, China.
Abstract:
Targeting the immune checkpoint programmed cell death-ligand 1 (PD-L1) faces diverse challenges against pancreatic ductal adenocarcinoma (PDAC), the most common type of cancer-related death. Shedding of PD-L1 from the tumor cell surface by A Disintegrin And Metalloprotease 10 (ADAM10) may impede the function of antitumor immune cells. Understanding the molecular mechanisms behind this interaction is urgently needed. This study elucidates the mechanism of ADAM10/PD-L1 interaction in the pancreatic adenocarcinoma cell line, PANC-1, using cellular assays, molecular docking, and molecular dynamics (MD) simulations. Cellular assays validated that ADAM10 interacts with PD-L1 and sheds the PD-L1 from the cell surface, generating soluble PD-L1 (sPD-L1). Concurrently, the docking results identified critical residues and potential contact points, providing strong evidence for a stable and specific interaction between ADAM10 and PD-L1. The molecular dynamics (MD) simulations further confirmed the structural integrity of the ADAM10/PD-L1 complex, predicting its compactness and stability. These results elucidate how ADAM10 recognizes and interacts with PD-L1, facilitating its cleavage. Future work can leverage these findings to develop potent cancer immunotherapies that inhibit the ADAM10/PD-L1 interaction and the generation of soluble molecules.
Insights
Researchers uncovered how A Disintegrin And Metalloprotease 10 (ADAM10) interacts with programmed cell death-ligand 1 (PD-L1) in pancreatic cancer. This interaction leads to PD-L1 shedding, impacting immune response and offering new therapeutic targets.
Area of Science:
- Immunology
- Molecular Biology
- Oncology
Background:
- Pancreatic ductal adenocarcinoma (PDAC) presents significant challenges in cancer therapy.
- Targeting immune checkpoints like programmed cell death-ligand 1 (PD-L1) is a promising strategy, but its efficacy is hindered by complex tumor microenvironments.
- The shedding of PD-L1 by A Disintegrin And Metalloprotease 10 (ADAM10) is a potential mechanism that impairs anti-tumor immunity in PDAC.
Purpose of the Study:
- To elucidate the molecular mechanism by which ADAM10 interacts with and cleaves PD-L1 on pancreatic cancer cells.
- To investigate the structural basis of the ADAM10-PD-L1 interaction using computational methods.
- To provide insights into potential therapeutic strategies targeting this interaction for PDAC treatment.
Main Methods:
- Utilized the PANC-1 pancreatic adenocarcinoma cell line for experimental validation.
- Employed cellular assays to confirm the interaction and shedding of PD-L1.
- Performed molecular docking and molecular dynamics (MD) simulations to analyze the binding interface and complex stability.
Main Results:
- Cellular assays confirmed that ADAM10 directly interacts with PD-L1 and mediates its shedding, generating soluble PD-L1 (sPD-L1).
- Molecular docking identified specific residues and contact points crucial for a stable and specific ADAM10-PD-L1 interaction.
- MD simulations demonstrated the structural integrity, compactness, and stability of the ADAM10/PD-L1 complex.
Conclusions:
- ADAM10 recognizes and binds to PD-L1, leading to its subsequent cleavage from the cell surface.
- Understanding this interaction mechanism is critical for developing novel cancer immunotherapies.
- Inhibiting the ADAM10-PD-L1 interaction could represent a viable strategy to enhance anti-tumor immunity in PDAC.
